AXGN

SEC source: 0000805928-21-000179 · wf-form4_164081264670254.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,436

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on December 27, 2021.

SEC source: 0000805928-21-000178 · wf-form4_164081251560102.xml · derivative · entry 3

Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,150

Underlying: Common Stock · 2,300 shares

Expires 2022-12-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of theaggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting personupon the vesting date.

F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of theaggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting personupon the vesting date.

SEC source: 0000805928-21-000178 · wf-form4_164081251560102.xml · nonDerivative · entry 2

Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,184

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-21-000178 · wf-form4_164081251560102.xml · nonDerivative · entry 1

Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on December 27, 2021.

SEC source: 0000805928-21-000176 · wf-form4_164020724990588.xml · derivative · entry 3

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,900 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-21-000176 · wf-form4_164020724990588.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,169

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-21-000176 · wf-form4_164020724990588.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,926

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2021.

SEC source: 0000805928-21-000177 · wf-form4_164020733379564.xml · derivative · entry 3

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-21-000177 · wf-form4_164020733379564.xml · nonDerivative · entry 2

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 923,029

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-21-000177 · wf-form4_164020733379564.xml · nonDerivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 924,272

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2021.

SEC source: 0000805928-21-000175 · wf-form4_164020715735933.xml · derivative · entry 3

Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 375 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-21-000175 · wf-form4_164020715735933.xml · nonDerivative · entry 2

Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,588

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-21-000175 · wf-form4_164020715735933.xml · nonDerivative · entry 1

Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2021.

SEC source: 0000805928-21-000174 · wf-form4_164020706647634.xml · derivative · entry 3

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 375 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-21-000174 · wf-form4_164020706647634.xml · nonDerivative · entry 2

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,119

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-21-000174 · wf-form4_164020706647634.xml · nonDerivative · entry 1

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,214

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on December 18, 2021.

SEC source: 0000805928-21-000173 · wf-form4_164020697971757.xml · derivative · entry 3

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 575 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-21-000173 · wf-form4_164020697971757.xml · nonDerivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,686

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units on December 18, 2021. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-21-000173 · wf-form4_164020697971757.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,830

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2021.

SEC source: 0000805928-21-000172 · wf-form4_163977493108416.xml · derivative · entry 3

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2021-12-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-21-000172 · wf-form4_163977493108416.xml · nonDerivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,255

F2 · shares: Represents the number of shares swapped to cover the exercise price of the options exercised via an attestation method stock swap in accordance with Rule16b-3.

SEC source: 0000805928-21-000172 · wf-form4_163977493108416.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,426

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of shares that became vested as of December 29, 2018.

SEC source: 0000805928-21-000171 · wf-form4_163822016284363.xml · derivative · entry 2

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,125

Underlying: Common Stock · 52,375 shares

Expires 2026-12-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time.

F2 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option will be fully vested on December 29, 2020 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 29, 2017 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-21-000171 · wf-form4_163822016284363.xml · nonDerivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 921,147

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time.

SEC source: 0000805928-21-000165 · wf-form4_162914459993109.xml · derivative · entry 4

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 46,500 shares

Expires 2021-12-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time.

F3 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on December 29, 2018 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 29, 2015 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-21-000165 · wf-form4_162914459993109.xml · nonDerivative · entry 2

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 868,772

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time.

SEC source: 0000805928-21-000165 · wf-form4_162914459993109.xml · derivative · entry 3

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,746

Underlying: Common Stock · 8,254 shares

Expires 2022-12-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time.

F2 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on December 28, 2019 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 28, 2016 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-21-000165 · wf-form4_162914459993109.xml · nonDerivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 822,272

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time.

SEC source: 0000805928-21-000163 · wf-form4_162862871653373.xml · derivative · entry 6

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 75,000 shares

Expires 2022-12-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time.

F6 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on December 29, 2019 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 29, 2016 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-21-000163 · wf-form4_162862871653373.xml · nonDerivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 855,018

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time.

SEC source: 0000805928-21-000163 · wf-form4_162862871653373.xml · nonDerivative · entry 5

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 814,018

F5 · shares: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with the November 19, 2018 and December 19, 2018 stock option exercises. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.075 to 19.40, inclusive.

F5 · price: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with the November 19, 2018 and December 19, 2018 stock option exercises. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.075 to 19.40, inclusive.

SEC source: 0000805928-21-000163 · wf-form4_162862871653373.xml · nonDerivative · entry 4

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 816,101

F4 · shares: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with the November 19, 2018 and December 19, 2018 stock option exercises. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.20 to 18.69, inclusive.

F4 · price: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with the November 19, 2018 and December 19, 2018 stock option exercises. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.20 to 18.69, inclusive.

SEC source: 0000805928-21-000163 · wf-form4_162862871653373.xml · nonDerivative · entry 3

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 839,003

F3 · shares: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with a performance stock award that vested on February 15, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.08 to 19.40, inclusive.

F3 · price: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with a performance stock award that vested on February 15, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.08 to 19.40, inclusive.

SEC source: 0000805928-21-000163 · wf-form4_162862871653373.xml · nonDerivative · entry 2

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 840,262

F2 · shares: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with a performance stock award that vested on February 15, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.20 to 18.69, inclusive. The reporting person undertakes to provide to Axogen, Inc., any security holder of Axogen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.

F2 · price: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with a performance stock award that vested on February 15, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.20 to 18.69, inclusive. The reporting person undertakes to provide to Axogen, Inc., any security holder of Axogen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.

SEC source: 0000805928-21-000150 · wf-form4_162707076778290.xml · nonDerivative · entry 1

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,839

F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2020.

F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2020.

SEC source: 0000805928-21-000148 · wf-form4_162689855941312.xml · nonDerivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,426

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021.

SEC source: 0000805928-21-000147 · wf-form4_162689851942225.xml · nonDerivative · entry 2

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,774

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021.

SEC source: 0000805928-21-000146 · wf-form4_162689849261026.xml · nonDerivative · entry 2

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 780,018

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021.

SEC source: 0000805928-21-000145 · wf-form4_162689846251349.xml · nonDerivative · entry 2

Sandberg Eric · CIK 0001764446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,541

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021.

SEC source: 0000805928-21-000144 · wf-form4_162689844445878.xml · nonDerivative · entry 2

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,120

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021.

SEC source: 0000805928-21-000143 · wf-form4_162689842781572.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,026

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021.

SEC source: 0000805928-21-000142 · wf-form4_162689841095311.xml · nonDerivative · entry 2

Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,360

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021.

SEC source: 0000805928-21-000141 · wf-form4_162689838247457.xml · nonDerivative · entry 2

MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,867

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021.

SEC source: 0000805928-21-000140 · wf-form4_162689834317764.xml · nonDerivative · entry 2

Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,308

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021.

SEC source: 0000805928-21-000148 · wf-form4_162689855941312.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,818

F1 · shares: This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria.

SEC source: 0000805928-21-000147 · wf-form4_162689851942225.xml · nonDerivative · entry 1

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,411

F1 · shares: This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria.

SEC source: 0000805928-21-000146 · wf-form4_162689849261026.xml · nonDerivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 788,830

F1 · shares: This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria.

SEC source: 0000805928-21-000145 · wf-form4_162689846251349.xml · nonDerivative · entry 1

Sandberg Eric · CIK 0001764446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,631

F1 · shares: This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria.

SEC source: 0000805928-21-000144 · wf-form4_162689844445878.xml · nonDerivative · entry 1

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,757

F1 · shares: This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria.

SEC source: 0000805928-21-000143 · wf-form4_162689842781572.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,944

F1 · shares: This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria.